IMAB
IMAB
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $7.114M ▲ | $-5.504M ▼ | 0% | $-0.069 ▲ | $-7.114M ▼ |
| Q1-2025 | $0 | $5.266M ▼ | $-3.15M ▲ | 0% | $-0.28 ▼ | $-5.266M ▲ |
| Q4-2024 | $0 | $13.371M ▲ | $-9.062M ▲ | 0% | $-0.11 ▲ | $-12.098M ▲ |
| Q3-2024 | $0 | $12.412M ▼ | $-20.491M ▼ | 0% | $-0.25 ▼ | $-12.412M ▲ |
| Q2-2024 | $0 | $258.954M | $25.126M | 0% | $0.3 | $-103.081M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $165.614M ▼ | $206.708M ▼ | $9.975M ▼ | $196.733M ▼ |
| Q1-2025 | $168.622M ▼ | $208.941M ▼ | $10.6M ▼ | $198.341M ▼ |
| Q4-2024 | $173.398M ▼ | $212.68M ▼ | $11.52M ▼ | $201.16M ▼ |
| Q3-2024 | $184.391M ▼ | $232.682M ▼ | $14.799M ▼ | $217.883M ▼ |
| Q2-2024 | $1.508B | $253.827M | $17.194M | $236.633M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-13.268M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q1-2025 | $-22.869M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2024 | $-66.144M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $-143.798M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $180.072M | $0 | $0 | $0 | $0 | $0 |
Revenue by Products
| Product | Q3-2020 | Q4-2020 | Q2-2022 | Q4-2022 |
|---|---|---|---|---|
 Grant | $10.00M ▲ | $0 ▼ | $0 ▲ | $20.00M ▲ |
 Licensing and Collaboration | $0 ▲ | $0 ▲ | $20.00M ▲ | $0 ▼ |
 Supply Of Investigational Products | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
About I-Mab
https://www.i-mabbiopharma.comI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $7.114M ▲ | $-5.504M ▼ | 0% | $-0.069 ▲ | $-7.114M ▼ |
| Q1-2025 | $0 | $5.266M ▼ | $-3.15M ▲ | 0% | $-0.28 ▼ | $-5.266M ▲ |
| Q4-2024 | $0 | $13.371M ▲ | $-9.062M ▲ | 0% | $-0.11 ▲ | $-12.098M ▲ |
| Q3-2024 | $0 | $12.412M ▼ | $-20.491M ▼ | 0% | $-0.25 ▼ | $-12.412M ▲ |
| Q2-2024 | $0 | $258.954M | $25.126M | 0% | $0.3 | $-103.081M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $165.614M ▼ | $206.708M ▼ | $9.975M ▼ | $196.733M ▼ |
| Q1-2025 | $168.622M ▼ | $208.941M ▼ | $10.6M ▼ | $198.341M ▼ |
| Q4-2024 | $173.398M ▼ | $212.68M ▼ | $11.52M ▼ | $201.16M ▼ |
| Q3-2024 | $184.391M ▼ | $232.682M ▼ | $14.799M ▼ | $217.883M ▼ |
| Q2-2024 | $1.508B | $253.827M | $17.194M | $236.633M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-13.268M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q1-2025 | $-22.869M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2024 | $-66.144M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $-143.798M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $180.072M | $0 | $0 | $0 | $0 | $0 |
Revenue by Products
| Product | Q3-2020 | Q4-2020 | Q2-2022 | Q4-2022 |
|---|---|---|---|---|
| Grant | $10.00M ▲ | $0 ▼ | $0 ▲ | $20.00M ▲ |
| Licensing and Collaboration | $0 ▲ | $0 ▲ | $20.00M ▲ | $0 ▼ |
| Supply Of Investigational Products | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
CEO
Xi-Yong Fu
Compensation Summary
(Year 2024)
CEO
Xi-Yong Fu
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Grade Summary
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
7.991M Shares
$32.045M
HHLR ADVISORS, LTD.
5.981M Shares
$23.982M
DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC
4.167M Shares
$16.708M
ADAGE CAPITAL PARTNERS GP, L.L.C.
3.338M Shares
$13.386M
MORGAN STANLEY
2.232M Shares
$8.95M
ARIOSE CAPITAL MANAGEMENT LTD
1.704M Shares
$6.835M
EXOME ASSET MANAGEMENT LLC
1.44M Shares
$5.773M
SIREN, L.L.C.
1.166M Shares
$4.675M
CANDRIAM S.C.A.
1.133M Shares
$4.542M
WOODLINE PARTNERS LP
1.05M Shares
$4.21M
POINT72 HONG KONG LTD
561.366K Shares
$2.251M
SG AMERICAS SECURITIES, LLC
463.894K Shares
$1.86M
BARCLAYS PLC
395.431K Shares
$1.586M
STATE STREET CORP
337.4K Shares
$1.353M
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
310.499K Shares
$1.245M
UBS GROUP AG
295.078K Shares
$1.183M
EDBI PTE LTD
222.136K Shares
$890.765K
GOLDMAN SACHS GROUP INC
218.47K Shares
$876.065K
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.
164.064K Shares
$657.897K
TEKLA CAPITAL MANAGEMENT LLC
162.58K Shares
$651.946K
Summary
Only Showing The Top 20